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Summary
Bisphenol A (BPA) is a widely used plasticizer whose
estrogenic properties may impact hormone-respon-
sive disorders and fetal development. In vivo, BPA
appears to have greater activity than is suggested by
its estrogen receptor (ER) binding affinity. This may
be a result of BPA sulfation/desulfation providing a
pathway for selective uptake into hormone-responsive
cells. BPA is a substrate for estrogen sulfotransferase,
and bisphenol A sulfate (BPAS) and disulfate are sub-
strates for estrone sulfatase. Although the sulfated xe-
nobiotics bind poorly to the ER, both stimulated the
growth of receptor-positive breast tumor cells. Treat-
ment of MCF-7 cells with BPAS leads to desulfation
and uptake of BPA. No BPAS is found inside the cells.
These findings suggest a mechanism for the selective
uptake of BPA into cells expressing estrone sulfatase.
Therefore, sulfation may increase the estrogenic po-
tential of xenobiotics.
Introduction
The role of estrogenic xenobiotics in hormone-respon-
sive neoplastic disease and disruption of normal endo-
crine function remains a source of considerable con-
troversy [1–6]. The xenoestrogen bisphenol A (BPA, 1,
Figure 1) has achieved particular notoriety in this regard.
BPA is a widely used plasticizer that may be found in
food packaging and dental sealants [7, 8]. BPA has
been implicated in a number of endocrine-related disor-
ders, from recurrent miscarriages to developmental dis-
ruptions associated with in utero exposure. Because of
its widespread use, there is a potential for continuous
low-level exposure, which may be of specific concern
for pregnant women and those with hormone-related
disorders. A recent study of the concentration of BPA
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Five Moore Drive, P.O. Box 13398, Research Triangle Park, North
Carolina 27513.in urine samples from 394 adults showed that 95% of
the samples contained BPA [9]. BPA binds with modest
affinity to the estrogen receptor (ER) and exhibits estro-
genic properties in tissue culture [10–13]. Because of its
modest binding affinity to the ER, its role in stimulating
hormonal responses in humans is controversial [14–
16]. Some of the questions that remain are (1) whether
or not the results in animal models are accurate and (2)
whether or not the results from animal models can be ex-
trapolated to humans. While the answers to these ques-
tions are still being debated, there seems to be a consen-
sus that there is a potential for deleterious effects from
exposure to BPA, as well as other xenoestrogens, and
further study is needed (see references cited above).
There has yet to be a determination of whether BPA rea-
ches sufficient concentration in target tissues to drive
binding to ERs. It is therefore critical to examine how
in vivo biochemical modifications of BPA and other
estrogenic xenobiotics affect their bioavailability and
potential to bind to relevant receptors.
Compounds such as BPA are subject to the activity of
phenol-sulfotransferases, a group of relatively promis-
cuous enzymes that mediate the sulfation of molecules
containing a phenol moiety (Figure 2) [17, 18]. While
the primary pathway for modification of ingested phe-
nols at high concentrations is glucuronidation, when
present at low concentrations sulfation is the more likely
modification [19, 20]. BPA is readily sulfated in tissue
culture by liver cells (HepG2) [21], and it has been
reported that estrogenic phenols such as BPA and
octylphenol are substrates for estrogen sulfotransferase
[21]. This enzyme efficiently mediates the sulfation of
steroids, which increases their water solubility and abil-
ity to circulate through the body [22]. The ability of sulfo-
transferases to sulfate BPA is of critical importance in
evaluating the potential of this molecule to function as
an estrogen in vivo. Sulfation of phenols drastically
decreases their membrane permeability, which should
have a chemoprotective effect. Experiments with
HepG2 cells show that BPA is taken up by these cells,
sulfated, and actively transported out of the cells.
Once sulfated, the bisphenol A sulfate (BPAS, 2, Fig-
ure 1) is not capable of reentering the liver cells [21]. Sul-
fation may also reduce inherent binding to the ER, which
may further block its estrogenic effect and reduce the
stimulation of breast tumor cell growth [23]. These re-
sults suggest that sulfation does play a role in chemo-
protection against the effects of xenobiotics such as
BPA.
Sulfatases are a group of enzymes that catalyze the
hydrolysis of sulfate esters [24]. The opposing activity
of sulfatases and sulfotransferases determines the sul-
fation state of a variety of molecules, including steroids,
neurotransmitters, carbohydrates, and, possibly, pro-
teins (Figure 2) [25]. There is mounting evidence that es-
trone sulfatase, also known as arylsulfatase C, facilitates
the uptake of estrogens into breast cancer cells by
mediating the desulfation of estrone sulfate, the domi-
nant circulating estrogen in women [22, 26–28]. There
is both chemical and immunochemical evidence that
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membrane and is thus exquisitely poised to facilitate
the conversion of charged, impermeant molecules, such
as steroid sulfates, into neutral molecules capable of
entering the cell by passive diffusion [29, 30]. If this
sulfatase were to catalyze the hydrolysis of sulfated xe-
nobiotics such as BPA, it might also facilitate the uptake
of these molecules into tumor cells. In this case, sulfa-
tion would not result in chemoprotection, but it might
provide a mechanism for selective uptake of phenolic
xenoestrogens into cells expressing sulfatases. Given
this possibility, we sought to discover whether the rele-
vant human enzymes are capable of carrying out the
sulfation and desulfation of BPA.
Results and Discussion
Estrogen Sulfotransferase Activity
In vivo, the sulfation of estrone is carried out by estrogen
sulfotransferase. This sulfation results in an ionic mole-
cule that can be transported in the blood more easily.
Therefore, if BPA is sulfated via this pathway, it would
have to be a substrate for estrogen sulfotransferase. The
activity of estrogen sulfotransferase with BPA was deter-
mined by using an in vitro assay similar to one that has
been reported previously [31, 32]. BPA was incubated
with enzymatically synthesized [35S]30phosphoadenosine
50-phosphosulfate (PAPS) and estrogen sulfotransfer-
ase; the amount of sulfate transfer was determined
by separation of the products on a silica gel TLC plate,
followed by quantitation with phosphorimaging. BPA is
indeed a good substrate for estrogen sulfotransferase.
The average KM for BPA with estrogen sulfotransferase
is 17.9 mM. Figure 3 shows a typical Lineweaver-Burk
plot for estrogen sulfotransferase activity.
Figure 2. Pathway for the Interconversion of Phenols and Their
Sulfate Esters
The sulfation is carried out by a sulfotransferase with the con-
version of 30phosphoadenosine 50-phosphosulfate (PAPS) to
30phosphoadenosine 50-phosphate (PAP).
Figure 1. Structures of Relevant Compounds
Structure of bisphenol A (1), bisphenol A sulfate (2), bisphenol A
disufate (3), and p-acetylphenyl sulfate (4), a chromogenic sub-
strate for estrone sulfatase.Estrogen Receptor Binding
It has been reported that the ER binds BPA with an affin-
ity that is approximately 2000- to 5000-fold less than the
affinity for estradiol [10]. To evaluate the role of sulfation
in BPA binding to hormone receptors, we assayed BPAS
and bisphenol A disulfate (BPADS, 3, Figure 1) for ER
binding. A competitive binding assay was performed
by using cytosolic ER derived from human breast cancer
cells (MCF-7). The percentages of 3H-estradiol still
bound to the ER after treatment with increasing concen-
trations of BPA (-), BPAS (:), and BPADS (d) are
graphed in Figure 4. The amount of estradiol bound to
the ER decreases linearly with increasing concentra-
tions of BPA. The amount of estradiol bound to the ER
decreases in a nonlinear manner with both BPAS and
BPADS. It takes about 10 times (BPAS) or 100 times
(BPADS) as much of the sulfated forms of BPA to dis-
place the same amount of estradiol from the ER as
BPA. Therefore, the affinities for the sulfated forms of
BPA are w10- and 100-fold less than that for BPA.
This suggests that sulfation of BPA may actually func-
tion as a protective measure against ER binding if the
cells do not have a way to remove the sulfate group.
Figure 3. Representative Lineweaver-Burk Plot for the Sulfation of
Bisphenol A by Estrogen Sulfotransferase
Figure 4. Competitive Binding for the Estrogen Receptor
Competitive binding assay with bisphenol A (-), bisphenol A sul-
fate (:), and bisphenol A disulfate (d) to displace labeled estradiol
from the estrogen receptor.
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893Estrone Sulfatase Activity
We have shown that BPA is a substrate for estrogen
sulfotransferase. Therefore, BPA can be sulfated by
the same enzyme as estrone. The question of whether
the sulfated forms can be desulfated by enzymes that
desulfate estrone sulfate remains. Estrone sulfatase,
the enzyme responsible for desulfating estrone sulfate,
is overexpressed in MCF-7 cells, which are ER-positive
breast tumor cells, and in placental cells. We therefore
tested BPAS and BPADS as substrates for this enzyme.
Because it is difficult to directly assay these molecules
as substrates for estrone sulfatase, the binding of these
molecules was determined indirectly by monitoring their
ability to inhibit the hydrolysis of p-acetylphenyl sulfate
(4, Figure 1) (The Ki for a competitive substrate is equal
to the KM for the substrate [33].). Both the monosulfate
and disulfate bind with micromolar affinity, 88.5 mM
and 13.4 mM, respectively, to estrone sulfatase. Figure 5
shows the replots of the slopes of the Lineweaver-Burk
plots that were used to determine the Ki. The ability of
these compounds to serve as substrates for the enzyme
was then confirmed with NMR by following the enzyme-
catalyzed conversion of the disulfate to the monosul-
fate, and the monosulfate to BPA (data not shown).
These experiments show that BPA can be sulfated and
desulfated in vitro by the same enzymes that sulfate
and desulfate estrone in vivo. It should be noted that
estrone sulfatase may be only one of several enzymes
that mediate the desulfation of arylsulfates in and around
breast tumor cells, but it is likely that BPAS and BPADS
would be substrates for these enzymes as well [34].
Figure 5. Binding Affinity for Estrone Sulfatase
(A and B) Secondary replots of slopes from Lineweaver-Burk plots
for (A) bisphenol A monosulfate and (B) bisphenol A disulfate.MCF-7 Cell Growth Stimulation
It has been suggested that the sulfation of BPA is pro-
tective because sulfated BPA cannot penetrate the cell
membrane in liver cells. We wanted to determine if the
same protection would be seen in breast cancer cells,
which are known to overexpress estrone sulfatase. Shi-
mizu et al. showed that levels of BPAS as high as 100 nM
do not promote the growth of MCF-7 cells [23]. However,
these concentrations of BPAS would not be high enough
to saturate estrone sulfatase, and, consequently, the de-
sulfation process would likely be very slow. We there-
fore assayed BPA, BPAS, and BPADS at higher concen-
trations for the ability to promote growth of ER-positive
breast cancer cells. In spite of the fact that both sulfated
molecules have much lower affinity for the ER than BPA,
they do stimulate the growth of MCF-7 cells. Figure 6
shows the growth of MCF-7 cells after treatment with es-
tradiol and varying concentrations of BPA, BPAS, and
BPADS. As would be expected, treatment with estradiol
increased the growth of cells by about 3.5 times what
was seen in the untreated control. At the lowest concen-
tration of BPA, the cell growth was similar to that of the
control. However, increasing the concentration of BPA
increased the cell growth over that of the control. Treat-
ment with concentrations of BPAS and BPADS up to
1 mM resulted in little or no increase in cell growth over
the control, which was similar to the results reported
by Shimizu et al. However, treatment with a concentra-
tion of 10 mM BPAS or BPADS increased cell growth
by the same amount or more than treatment with the
same concentration of BPA. It is unlikely that the binding
of BPADS to the ER is causing the growth, because even
at 10 mM BPADS only about 10% of bound estradiol was
displaced from the ER. It is more likely that the increase
in cell growth at 10 mM BPAS or BPADS is the result of
BPA binding to the ER for the following reason. At con-
centrations up to 1 mM BPAS or BPADS, the enzymatic
desulfation would be slow; therefore, the growth of the
cells would also be slow relative to the assay time. At
higher concentrations, the desulfation would be faster,
and the rate of cell growth would also be faster. It is
Figure 6. Stimulation of MCF-7 Cell Growth
Stimulation of MCF-7 cell growth by estradiol (E2, 1 nM) and differ-
ent molar concentrations of bisphenol A (BPA, 10 nM–10 mM),
bisphenol A sulfate (BPAS, 100 nM–10 mM), and bisphenol A disul-
fate (BPADS, 100 nM–10 mM). Error bars were determined from four
replicative samples of each treatment.
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(A–D) HPLC traces of (A) the media at t = 0 hr after treating cells with bisphenol A sulfate (BPAS), (B) the media at t = 36 hr after treating cells with
BPAS, (C) the final ether extract of the NaOH wash of cells treated with BPAS, and (D) the final ether extract of the NaOH wash for control cells.also possible that the binding of BPAS to the ER is re-
sponsible for the increased growth. It was therefore crit-
ical to determine which form of BPA was present in the
tumor cells.
Determination of the Bioactive Form of BPA
To determine whether BPAS can penetrate cells ex-
pressing estrone sulfatase, and to see whether removal
of the sulfate group is required for uptake, MCF-7 cellswere treated with 3H-BPAS. After incubation, the media
were collected and the cells were harvested and lysed.
HPLC analysis and scintillation counting showed that
the media contained some of the labeled BPAS, and
that the rest of the radiolabel was associated with the
cell debris (data not shown). An initial control was per-
formed by using vesicles constructed of 1,2-distearoyl-
sn-glycero-3-phosphocholine to determine whether BPA
could be extracted from a membrane-like environment
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BPAS. The vesicles were treated with a solution contain-
ing a mixture of BPA and BPAS that was shaken gently
overnight. The vesicles were then washed with 1 N
NaOH. The NaOH solution was extracted with ether,
neutralized to wpH 7, and again extracted with ether.
The final ether extract contained both BPA and BPAS
(results not shown). This indicated that the extraction
conditions would not desulfate BPAS and that both
BPA and BPAS could be extracted from vesicles, and
presumably membranes, by using this technique. In a
subsequent assay, MCF-7 cells were treated with
BPAS, the media and cells were separated, and the cells
were washed with 1 M NaOH. The NaOH solution was
extracted as described above. The media and the result-
ing ether extracts were submitted to HPLC analysis (see
Figure 7). HPLC traces resulting from injections of ali-
quots of the media, shown in Figures 7A and 7B, show
a decrease in the concentration of BPAS (retention
time = 19 min) outside the cell over time. However, there
was no increase in BPA (retention time = 24 min) in the
media. Traces resulting from the final ether extract for
cells treated with BPAS show only one large peak with
a retention time of 24 min. This peak coeluted with
BPA when the sample was spiked with pure compound.
Ether extracts of control cells not treated with BPAS did
not have a peak at 24 min. These results clearly show
that BPA, not BPAS, is absorbed by MCF-7 cells treated
with BPAS. Therefore, the estrogenic response in MCF-7
cells must be the result of BPA, not BPAS, binding to the
ER. It is important to note that there was no BPA found in
the media, and that all of the BPA produced was found
inside the cells. This apparent coupling of desulfation
and uptake of BPA suggests a pathway for increasing
the concentration of BPA inside cells capable of desul-
fating BPAS and BPADS, such as receptor-positive
breast tumor cells and placental cells. Previously, sulfa-
tion was thought to facilitate the excretion of xenobi-
otics [21]. In light of these data, it must be considered
that sulfation of xenobiotics may actually enhance their
estrogenic activity in cells that have the ability to hydro-
lyze the sulfate group.
Significance
In vivo studies reveal a higher estrogenic activity for
BPA than can be accommodated by simple receptor
binding data, which may be the result of the existence
of an unknown BPA metabolite [6]. One of the main
pathways for metabolizing xenobiotics is the addition
of a sulfate group. Estrogen sulfation promotes in-
creased estrogen uptake into cells that express sulfa-
tases [35]. Similarly, it is possible that the potency of
BPA may be enhanced as a consequence of sulfation,
which leads to selective uptake in tissues that express
sulfatases on their exterior. We have confirmed that
BPA is sulfated and desulfated by the same enzymes
as estrone, and that sulfated versions of BPA stimu-
late breast cancer cell growth. We have also shown
that when MCF-7 cells are treated with BPAS, the con-
centration of BPAS outside the cell decreases over
time with the concurrent appearance of BPA inside
the cells. There is no BPAS associated with the cells.
Taken together, these findings demonstrate that anenzymatic pathway for sulfation and desulfation of
BPA by human enzymes exists in vitro and suggests
that the pathway may also be active in vivo. It should
be stressed that none of the data presented here ad-
dress the existence of an in vivo pathway. However,
the presence of these enzymes in humans and the se-
lective overexpression of estrone sulfatase in various
tissues raise important questions about the pathway
of xenoestrogen uptake into these cells. This, in turn,
suggests that more attention needs to be focused
on determining whether the sulfated metabolites of
BPA, and other xenoestrogens, may be implicated in
the low-dose biological effects of these compounds.
Experimental Procedures
Estrogen Sulfotransferase Activity
Estrogen sulfotransferase (EST) activity was measured in 50 ml
20 mM Tris-HCl (pH 7.4), containing 1 mM EDTA, by using 20 mg
EST and 0.098–100 mM bisphenol A (BPA) for KM determination.
The reactions were initiated by the addition of 2.5 nM enzymatically
synthesized 35S-PAPS [36], and they were quenched after a 10 min
incubation at room temperature with 50 ml methanol. Half of the
quenched reaction (50 ml) was applied to the loading lane of What-
man 10 3 20 silica plates and was eluted with 8:2:1 butanol:etha-
nol:H2O (3 hr). The plates were air dried, and the amount of radiolabel
incorporated into bisphenol A sulfate (BPAS) was quantified by
phosphorimaging. This method is similar to a method for screening
against several other sulfotransferases [31, 32].
Synthesis of Bisphenol A Sulfate and Bisphenol A Disulfate
BPAS and bisphenol A disulfate (BPADS) were synthesized from BSA
(Aldrich) and sulfur trioxide pyridinium complex (Aldrich) as follows.
BPAS
BSA and 1.1 equivalents of sulfur trioxide were stirred in dry pyridine
under argon for 36 hr. The solvent was removed under reduced pres-
sure, and the crude reaction mixture was purified by column chro-
matography (10% methanol in CH2Cl2). The pyridinium salt was dis-
solved in water and passed down a Dowex 50W X-8 cation exchange
column, sodium form. 1H-NMR (CD3OD, 300 MHz): d7.18 (s, 4H), 7.02
(2H, d, J = 8.8 Hz), 6.67 (2H, d, J = 8.8 Hz), 1.6 (6H, s), 13C-NMR
(CD3OD, 101 MHz): d 156.2, 151.5, 149.2, 142.7, 126.7, 128.4,
121.9, 115.6, 42.8, 31.5. ESIMS (negative ion mode) 291 (BPAS
monoanion).
BPADS
BSA and 3.8 equivalents of sulfur trioxide were stirred in dry pyridine
for 24 hr. The solvent was removed under reduced pressure. The re-
maining mixture was dissolved in ddH2O, washed five times with
CH3Cl, washed three times with ether, and passed down a Dowex
50W X-8 cation exchange column, sodium form. 1H-NMR (D2O,
400 MHz): d 7.13 (2H, d, J = 7.7 Hz), 7.02 (2H, d, J = 7.7 Hz), 1.48
(s, 6H), 13C-NMR (CD3OD, 101 MHz): d 148.9, 148.6, 128.1, 120.9,
41.9, 29.9. ESIMS (negative ion mode) 386.9 (BPADS monoanion).
Relative Estrogen Receptor Binding
Estrogen receptor (ER) binding was performed as described previ-
ously [37]. A human breast cell cytosol was prepared from MCF-7
cells and diluted to 1 mg protein/ml. Each assay tube contained
100 ml diluted cytosol and 2.5 nM [3H]estradiol (E2) (Amhersham, Ar-
lington, IL) plus test compound (BPA or sulfated BPAs) at 1026–1024
M. The tubes were incubated for 18 hr at 4C, and then a suspension
of dextran-coated charcoal was added to remove free [3H]E2. Bound
[3H]E2 was extracted from the supernatant with ethanol, and the ra-
dioactivity was determined by liquid scintillation. The protein bound
radiolabel was expressed as a percentage of maximum binding (in
the absence of competitor) and was plotted against the concentra-
tion of competitor.
Breast Cancer Cell Growth Assays
MCF-7 breast cancer cells were propagated in DMEM supple-
mented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT)
and 6 mg/ml insulin (Sigma Chemical Co., St. Louis, MO). To test
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896the growth response, MCF-7 cells were plated at 15,000 cells per
well in 4-well plates (well diameter: 18 mm) (Nunc, Naperville, IL) in
phenol red-free medium (PRF-DMEM) containing 3% charcoal-
stripped FBS (Hyclone) plus 6 mg/ml insulin. Two days later, medium
was replaced with fresh medium containing treatments. Each well of
individual plates was treated with test compound: 1029 M E2, or
1028–1025 M BPA, BPAS, or BPADS. The medium was replaced
every 2 days until the eighth day of treatment. The number of live
cells present in each culture well was determined by using a colori-
metric assay based on the biochemical reduction of a tetrazolium
salt, MTT (Sigma), to form a blue formazan product [38]. Briefly, me-
dium was removed from the cells, and a solution of MTT (1 mg/ml in
PRF-DMEM) was added. The cells were incubated in the MTT solu-
tion for 3 hr at 37C and then developed by the addition of acidic iso-
propanol (0.04 N HCl in isopropanol). The optical density (OD) of the
isopropanol solution was read at 570 nm. Thus, treatment effects
were estimated by comparing the mean OD of control cultures
against the mean OD of four replicate samples of each treatment.
HPLC Analysis
MCF-7 cells were prepared as described for the cell growth assays,
with the exception of using six-well plates (well diameter: 35 mm).
The cells were treated with either water or enough BPAS in water
to make a final concentration of 250 mM BPAS. After incubation for
36 hr, the media were collected and reserved for HPLC analysis.
The cells were washed with water to remove any remaining media.
The water was collected and reserved for HPLC analysis. The cells
were washed with 1 M NaOH. The NaOH solution was collected, ex-
tracted with ether, neutralized with 1 M HCl, and extracted with ether
again. The ether solution was collected and reserved for HPLC anal-
ysis. All HPLC analysis was carried out by using a 300 mm3 3.9 mm
alphaBond-C18 125A analytical column (Alltech Associates Inc.,
Deerfield, IL), eluted with a mobile phase of water/acetonitrile,
both containing 1% acetic acid, at a flow rate of 1 ml/min. The total
run time was 55 min. The mobile phase gradient was run with 95%
water and 5% acetonitrile for 5 min, then with 5% water and 95%
acetonitrile over 25 min. These conditions were maintained for
5 min, until the column was brought back to initial conditions over
15 min. The HPLC system used throughout this work was composed
of a 600E HPLC pump (Waters). The column effluent was monitored
in tandem with a UV-visible detector (Waters 2487) at a wavelength
of 270 nm.
Estrone Sulfatase Activity
Kis were determined for both BPAS and BPADS by measuring the in-
hibition of the hydrolysis of p-acetylphenyl sulfate (Aldrich). Enzyme
assays were carried out in 1.5 ml polypropylene microcentrifuge
tubes. Estrone sulfatase was purified from fresh human placenta
as previously reported [39]. Estrone sulfatase, 15.7 units, was prein-
cubated for 10 min at 37C with 520ml 20 mM Tris-Cl (Promega) buffer
(pH 7.4) containing varying concentrations of either BPAS or BPADS.
A total of 140 ml buffer containing p-acetylphenyl sulfate at varying
concentrations (preequilibrated to 37C) was added to the enzyme
mixture. Aliquots (100 ml) were removed at T = 2, 4, 6, 8, and 10 min
and were quenched into 600 ml 1.4 N NaOH. Absorbance readings
for p-acetylphenoxide were measured at 325 nm (3 = 21,000 M21
cm21). The Ki for each inhibitor was determined from Lineweaver-
Burk plots and secondary replots of the slopes of Lineweaver-Burk
plots versus the corresponding inhibitor concentration.
NMR Assays for Enzyme-Catalyzed Conversion
Enzyme assays were carried out in 15 ml polypropylene conical
tubes. A total of 2.4 ml estrone sulfatase in 30 mM glycine buffer
(pH 7.4) containing 0.1% (w/v) Triton X-100 (Promega) and 0.02%
(w/v) sodium azide was incubated with 8.1 ml 4 mM BPAS or BPADS
in 30 mM glycine buffer (pH 7.4) containing 0.02% (w/v) Triton X-100
at 37C. At T = 17, 51, and 68 hr, 3.5 ml aliquots were removed, fro-
zen, and lyophilized to remove water. The lyophilized powder was
dissolved in DMSO-d6, and proton nuclear magnetic resonance
spectra were obtained by using a Varian-400 (400 MHz). The chem-
ical shifts were determined in parts per million relative to the solvent
reference. These spectra were compared to spectra of the expected
products under the same conditions.Acknowledgments
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